{"entity":{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","aka":[],"tldr":"Co-discovered EGFR mutations in lung cancer and has led the drug development that followed, from osimertinib to KRAS G12C inhibitors.","summary":"Pasi A. Jänne is Director of the Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science at Dana-Farber Brigham Cancer Center. He is known for co-discovering in 2004 that EGFR mutations predict response to gefitinib in lung cancer, and for leading the drug development that followed, including FLAURA2 with osimertinib plus chemotherapy and the KRYSTAL-1 adagrasib lung study. His selected papers cover the activating EGFR mutations underlying gefitinib responsiveness, adagrasib in KRAS G12C-mutant lung cancer, and osimertinib with or without chemotherapy in EGFR-mutated lung cancer. He directs Dana-Farber's thoracic oncology centre and studies targeted therapy resistance.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/pasi-a-janne"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janne%20PA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","kras"],"drugs":["osimertinib","adagrasib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["flaura2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Lowe Center for Thoracic Oncology; Director, Belfer Center for Applied Cancer Science","institutionId":"dana-farber","specialisms":["EGFR-mutant lung cancer","Targeted therapy resistance","KRAS G12C"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/pasi-a-janne"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janne%20PA%5BAuthor%5D"}],"papers":[{"title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","journal":"New England Journal of Medicine","year":2004,"url":"https://doi.org/10.1056/NEJMoa040938","doi":"10.1056/NEJMoa040938"},{"title":"Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2204619","doi":"10.1056/NEJMoa2204619"},{"title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2306434","doi":"10.1056/NEJMoa2306434"}]},"route":"/people/pasi-janne/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/"}],"trial":[{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/"}],"paper":[{"id":"paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","kind":"paper","name":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","route":"/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/"},{"id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/"},{"id":"paper-paez-egfr-mutations-gefitinib-science-2004","kind":"paper","name":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","route":"/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/"},{"id":"paper-flaura2-long-term-safety-lung-cancer-2026","kind":"paper","name":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","route":"/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/"},{"id":"paper-engelman-met-amplification-gefitinib-resistance-science-2007","kind":"paper","name":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","route":"/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/"},{"id":"paper-awad-met-exon-14-mutations-lung-jco-2016","kind":"paper","name":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","route":"/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/"},{"id":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","kind":"paper","name":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","route":"/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/"}]}}